Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS)
Table 1
Baseline characteristics.
Characteristics
Total (n = 18)
Age, mean ± SD (years)
62.2 ± 10.0
Male sex, n (%)
12 (66.7)
Body mass index, median (IQR) (kg/m2)
25.6 (23.3–27.4)
Ethnicity, n (%)
Caucasian
17 (94.4)
African American
1 (5.6)
Cardiovascular-related history, n (%)
Hypertension
12 (66.7)
Hypercholesterolemia
9 (50.0)
Smoking
7 (38.9)
Diabetes mellitus
4 (22.2)
Previous PCI
10 (55.6)
Previous CABG
1 (5.6)
Previous angina pectoris
7 (38.9)
Previous myocardial infarction
9 (50.0)
Stroke
2 (11.1)
Peripheral artery disease
1 (5.6)
Antihypertensive medications before PCIa, n (%)
Beta-blocker
16 (89)
ACE inhibitor or angiotensin II receptor blocker
15 (83)
Calcium channel blocker
3 (17)
Diuretics
3 (17)
Long-acting nitrate or intravenous nitroglycerin
9 (50)
Blood pressure, mean ± SD (mmHg)
Systolic
142 ± 22.8
Diastolic
82 ± 13.7
Heart rate, mean ± SD (beats/min)
70 ± 11.8
Infarct-related artery, n (%)
Left main
0
Left circumflex coronary artery
2 (11.1)
Left anterior descending coronary artery
5 (27.8)
Right coronary artery
5 (27.8)
No clear culprit defined
6 (33.3)
Number of vessels affected, n (%)b
0
5 (27.8)
1
7 (38.9)
2
6 (33.3)
Lab values at admission, median (IQR)
High sensitive troponin T (ng/L)
23 (15–30)
CK (U/L)
95 (62–140)
CK-MB (U/L)
12 (10–17)
NT-proBNP (ng/L)
132 (53–262)
Creatinine (μmol/L)
72 (66–84)
CK, creatine kinase; CK-MB, creatine kinase-myocardial band; IQR: interquartile range; NT-proBNP, N-terminal probrain natriuretic peptide; SD, standard deviation. aDefined as antihypertensive drug use before admission or at least 1 dose <24 hours before arrival at the catheterization laboratory. b≥70% reduction in the internal diameter of the right coronary artery, left anterior descending, or left circumflex coronary artery or ≥50% reduction in the internal diameter of the left main coronary artery.
